Related Experiment Video
Updated: May 5, 2026

08:51
Statistical Modelling of Cortical Connectivity Using Non-invasive Electroencephalograms
Published on: November 1, 2019
5.6K
A Novel CNN-Based Framework for Alzheimer's Disease Detection Using EEG Spectrogram Representations.
Konstantinos Stefanou1, Katerina D Tzimourta2, Christos Bellos1
1Department of Informatics and Telecommunications, University of Ioannina, Kostakioi, 47100 Arta, Greece.
Journal of Personalized Medicine
|January 24, 2025
Summary
This study introduces a deep learning model using EEG data to classify Alzheimer's disease (AD) and frontotemporal dementia (FTD). The novel approach shows promise for faster, more accessible dementia screening.
Area of Science:
- Neuroscience
- Medical Imaging
- Artificial Intelligence
Background:
- Alzheimer's disease (AD) and frontotemporal dementia (FTD) are progressive neurodegenerative disorders with increasing global prevalence.
- Current diagnostic methods for AD and FTD are slow and resource-intensive, highlighting the need for automated solutions.
- Early and accurate diagnosis is crucial for managing dementia effectively.
Purpose of the Study:
- To develop and evaluate a novel deep learning methodology for classifying Alzheimer's disease (AD), frontotemporal dementia (FTD), and control (CN) signals using electroencephalography (EEG).
- To assess the cross-subject generalizability and performance of the proposed deep learning model against existing state-of-the-art methods.
Main Methods:
- A deep learning approach utilizing Convolutional Neural Networks (CNNs) for EEG signal classification.
- Incorporation of advanced preprocessing techniques and Fast Fourier Transform (FFT)-based spectrograms for feature extraction.
- Evaluation using leave-N-subjects-out cross-validation to ensure robust generalizability across subjects.
Main Results:
- The proposed deep learning methodology achieved high accuracy in classifying dementia types from EEG signals.
- Achieved 79.45% accuracy for Alzheimer's disease (AD) versus control (CN) classification.
- Achieved 80.69% accuracy for the combined AD and FTD versus control (CN) classification.
Conclusions:
- Deep learning models applied to EEG data show significant potential for early dementia screening.
- The developed methodology offers a more efficient, scalable, and accessible approach to dementia diagnosis.
- This research paves the way for improved diagnostic tools for neurodegenerative disorders like AD and FTD.
Related Concept Videos
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21

